Active Ingredient(s): Tipranavir
FDA Approved: * June 22, 2005
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Aptivus Overview

Tipranavir (TPV), or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) manufactured by Boehringer Ingelheim under the trade name Aptivus /æptvs/ AP-tiv-s. It is administered with ritonavir in combination therapy to treat HIV infection. Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors and it recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mu...

Read more Aptivus Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tipranavir

Recent Aptivus Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 250mg
  • Solution: 100mg/ml, 250mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Aptivus: (2 results)

Sorted by National Drug Code
  • 0597-0002 Aptivus 100 mg/ml Oral Solution by Boehringer Ingelheim Pharmaceuticals, Inc.
  • 0597-0003 Aptivus 250 mg Oral Capsule by Boehringer Ingelheim Pharmaceuticals, Inc.

Other drugs which contain Tipranavir or a similar ingredient: (1 result)